Xiao-Bing Wang
China Pharmaceutical University
240 Papers
1K Citations
Xiao-Bing Wang is an academic researcher from China Pharmaceutical University. The author has contributed to research in topics: Chemistry & Trolox. The author has an hindex of 34, co-authored 240 publications.
Chat about Author
Papers
Multi-target tacrine-coumarin hybrids: cholinesterase and monoamine oxidase B inhibition properties against Alzheimer's disease.
Sai-Sai Xie,Xiao-Bing Wang,Neng Jiang,Wenying Yu,Kelvin D.G. Wang,Jin-Shuai Lan,Zhong-Rui Li,Ling-Yi Kong +7 more
TL;DR: Kinetic and molecular modeling studies revealed that 14c was a mixed-type inhibitor, binding simultaneously to catalytic, peripheral and mid-gorge sites of AChE, and was also a competitive inhibitor, which covered the substrate and entrance cavities of MAO-B.
154
Design, synthesis, and acetylcholinesterase inhibitory activity of novel coumarin analogues.
TL;DR: Pharmacological study and preliminary structure-activity relationships showed that coumarin analogues with substitution on positions 3 and/or 4 have parallel anti-AchE activities compared with the reference compound.
132
Design, synthesis and biological evaluation of imine resveratrol derivatives as multi-targeted agents against Alzheimer's disease.
TL;DR: Compound 9 is a potential lead compound for AD treatment and is capable of decreasing reactive oxygen species (ROS) induced by Cu-Aβ and shows good neuroprotective effects in human SH-SY5Y neuroblastoma cells.
104
Multifunctional tacrine-flavonoid hybrids with cholinergic, β-amyloid-reducing, and metal chelating properties for the treatment of Alzheimer's disease.
Su-Yi Li,Xiao-Bing Wang,Sai-Sai Xie,Neng Jiang,Kelvin D.G. Wang,Hequan Yao,Hongbin Sun,Ling-Yi Kong +7 more
TL;DR: A new series of tacrine-flavonoid hybrids (13a-u) had been designed, synthesized, and evaluated as multifunctional cholinesterase (ChE) inhibitors against Alzheimer's disease (AD).
95
Design, synthesis and evaluation of novel tacrine–rhein hybrids as multifunctional agents for the treatment of Alzheimer's disease
TL;DR: Kinetic and molecular modeling studies of 10b indicated that it was a mixed-type inhibitor binding simultaneously to the active and peripheral sites of AChE, and suggested that 10b might be an excellent multifunctional agent for AD treatment.
89